Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | S100B | P04271 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorobenzene SCHEMBL27825902 | 0.92 | TSHR (0.44) | CYP3A4AOC3CNR2ALDH1A1TSHR | |
| Fluorobenzene SCHEMBL28790461 | 0.85 | CNR2 (0.38) | CYP3A4AOC3CNR2TSHRMAPK1 | |
| Chlorobenzene SCHEMBL27805375 | 0.81 | TSHR (0.41) | CYP3A4AOC3CNR2ALDH1A1TSHR | |
| SCHEMBL15132705 | 0.79 | KCNH2 (0.45) | AOC3CNR2 | |
| SCHEMBL28895493 | 0.78 | ALDH1A1 (0.62) | CYP3A4ALDH1A1PSMD14TSHRMAPK1 | |
| SCHEMBL1826555 | 0.78 | ALDH1A1 (0.46) | CYP3A4CNR2LMNACYP2A6ALDH1A1 | |
| SCHEMBL2776268 | 0.76 | MAPK1 (0.43) | CYP3A4AOC3LMNAALDH1A1PSMD14 | |
| SCHEMBL2126003 | 0.75 | ALDH1A1 (0.46) | CYP3A4AOC3ALDH1A1TSHRTDP1 | |
| SCHEMBL20411970 | 0.75 | CNR2 (0.44) | CYP3A4CNR2LMNACYP2A6ALDH1A1 | |
| SCHEMBL2881066 | 0.75 | CNR2 (0.63) | CYP3A4CNR2ALDH1A1PSMD14TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907398-B | Chiral organic-inorganic hybridization symbiotic perovskite single crystal, growth method and application thereof | 闽都创新实验室 | 2023-12-05 | — | — | CN | disclosed |
| US-20170247355-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-10-24 | — | — | US | disclosed |
| EP-0763014-A1 | CARBAMOYL CARBOXYLIC ACID HYDRAZIDES AND THEIR USE AGAINST FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995033710-A1 | CARBAMOYL CARBOXYLIC ACID HYDRAZIDES AND THEIR USE AGAINST FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247355-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | CYP3A4 1668/4885AOC3 2963/4885CNR2 3658/4885 |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K8 | CYP3A4 983/4885AOC3 3241/4885CNR2 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.